| Xiulong Ma,Hongbing Ma,Dongli Ruan. Evaluation of endocrine therapy combined with intensity modulated radiation therapy in patients with advanced prostate cancer. Oncol Transl Med, 2021, 7: 229-234. |
| 内分泌治疗联合同期调强放疗对中晚期前列腺癌患者的疗效评估 |
| Evaluation of endocrine therapy combined with intensity modulated radiation therapy in patients with advanced prostate cancer |
| Received:April 16, 2021 Revised:October 20, 2021 |
| DOI：10.1007/s10330-021-0491-1 |
| 中文关键词: 适型调强放疗 内分泌治疗 前列腺癌 无转移生存率 |
| 英文关键词: conformal intensity-modulated radiation; endocrine therapy; prostate cancer; metastasis-free survival rate |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Xiulong Ma | The Second Affiliated Hospital of Xi''''an Jiaotong University, | 583513169@qq.com | | Hongbing Ma | Department of Radiotherapy, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710004, China | | | Dongli Ruan* | Department of Urology, Xijing Hospital, Air Force Military Medical University, Xi'an 710032, China | 745501416@qq.com |
|
| Hits: 5600 |
| Download times: 6400 |
| 中文摘要: |
| 目的 研究内分泌治疗联合同期调强放疗对中晚期前列腺癌患者的疗效。方法 收集2010年5月至2018年3月年我院共收治231例中晚期前列腺癌放疗患者的临床资料，135例行内分泌治疗联合同期调强放疗，98例因药物过敏、严重不良反应、经济原因等行单纯调强放疗治疗。治疗结束后2月通过影像学复查评估结果进行近期疗效判定，治疗前及治疗结束后2月均检测TPSA及FPSA，本研究所有患者均至少随访3年，统计两组无转移生存率及累计生存率。结果 观察组与对照组RR分别为64.45%、46.87%，差异无统计学意义（P＞0.05）；但内分泌治疗联合同期调强放疗组疗效分布明显优于单纯调强放疗组（P＜0.05）。两组患者不同TNM分期、不同Gleason分级的临床疗效比较无明显差异；治疗后TPSA、fPSA水平均较治疗前明显下降，但内分泌治疗联合同期调强放疗组下降幅度显著大于单纯调强放疗组，差异有统计学意义（P＜0.05）。两组治疗结束后1年、3年的累计生存率无统计学差异，但内分泌治疗联合同期调强放疗组1年、3年无转移生存率分别为60%、38.17%，明显高于单纯调强放疗组的37.5%、20.83%（P＜0.05）。结论 内分泌治疗联合同期调强放疗组可明显提高中晚期前列腺癌的临床治疗疗效，PSA水平明显降低，并提高无转移生存率。 |
| 英文摘要: |
| Objective The aim of this study was to study the effect of endocrine therapy combined with intensitymodulated radiation therapy in patients with advanced prostate cancer.
Methods The clinical data of 231 patients with advanced prostate cancer treated with radiotherapy in our
hospital from May 2010 to March 2018 were collected. A total of 135 patients were treated with endocrine
therapy combined with intensity-modulated radiotherapy, and 96 patients were treated with intensitymodulated radiotherapy only because of drug allergy, serious adverse reactions, and economic reasons.
Two months after the end of the treatment, the short-term curative effect was evaluated using imaging
reexamination. The total prostate-specific antigen (TPSA) and free prostate-specific antigen (FPSA) were
detected before and 2 months after the end of the treatment. All patients were followed up for at least 3
years, and the metastasis-free survival rate and cumulative survival rate of the two groups were calculated.
Results The remission rates (RRs) of the observation and control groups were 64.45% and 46.87%,
respectively; the difference was not statistically significant (P > 0.05); however, the efficacy distribution
of the endocrine therapy combined with intensity-modulated radiotherapy group was significantly better
than that of the intensity-modulated radiotherapy group (P < 0.05). There was no significant difference in
clinical efficacy between the two groups in different TNM stages and Gleason grades. After treatment, the
levels of TPSA and FPSA were significantly decreased compared with those before treatment; however,
the decrease in the endocrine therapy combined with the intensity-modulated radiation therapy (IMRT)
group was significantly higher than that in the IMRT group (P < 0.05). Although there were no significant
differences in the 1-year and 3-year cumulative survival rates between the two groups, the 1-year and
3-year metastasis-free survival rates of the endocrine therapy combined with the IMRT group were 60%
and 38.17%, respectively, which were significantly higher than those of the IMRT group (37.5% and 20.83%,
P < 0.05).
Conclusion Endocrine therapy combined with IMRT significantly improved the clinical efficacy of
advanced prostate cancer, reduced PSA (prostate specific antigen) levels, and improved the metastasisfree survival rates. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|